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INTRODUCTION 
The polyamines putrescine, spermidine and spermine are present in almost all 
cells and have important roles in protein synthesis, cell division and cell growth (Fig. 1). 
Putrescine is synthesized from L-ornithine in a reaction catalyzed by ornithine 
decarboxylase, the rate-limiting enzyme in polyamine biosynthesis. Putrescine and 
decarboxylated S-adenosyl methionine are substrates for the synthesis of spermidine, 
which is a precursor of spermine. Polyamines are organic polycations that are 
protonated at physiological pH and can potentially interact with a variety of cellular 
targets including nucleic and proteins [1-4]. 
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Fig. 1  Structure of polyamines 
 
The endogenous polyamines putrescine, spermidine and in particular, 
spermine modulate a number of ion channel [5, 6]. Spermine and spermidine are present 
in high concentration in the nervous system, and uptake and depolarization-induced 
release of polyamines from brain slices has been reported [7, 8]. Extracellular spermine 
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has multiple effects at the NMDA subtype of glutamate receptor, including stimulation 
that increases the size of NMDA receptor currents and voltage-dependent block [9-15]. 
 
Activation of NMDA receptors is associated with the induction of various 
forms of synaptic plasticity, including some forms of long-term potentiation and 
long-term depression, processes that may underlie learning and memory [16-18]. 
NMDA receptors are subtype of ligand-gated ionotropic glutamate receptors including 
subtypes of AMPA and kainite receptors [19]. Although they share common structural 
features, NMDA receptors have several characteristics different from the other two 
subtypes of glutamate receptors; 1) Not only glutamate but also glycine are necessary 
for activation of NMDA receptors; 2) NMDA receptors show high permeability to Ca2＋; 
and 3) NMDA receptor activity is blocked by Mg2＋ at resting membrane potential and 
the block is relieved by depolarization[19]. 
 
       At native NMDA receptors expressed on cultured neurons, there is 
considerable variability in the degree of stimulation by spermine of individual neurons 
[11-14]. This may be due to the expression of multiple forms of the NMDA receptor 
composed of different combinations of subunits. The NR1 family consists of eight 
splice variants of the NR1 gene [20-23], eight of which were originally termed 
NR1A-NR1H [24]. The NR2 family consists of NR2A, NR2B, NR2C and NR2D cDNA 
isolated from rat brain [25-28]. High active NMDA receptor channel is formed in vitro 
by co-expression of NR1 and NR2 subunits [25, 26, 29, 30], although the NR1 subunit 
alone exhibits a very small response in the Xenopus oocyte expression system [21, 31]. 
In accord with this, most brain regions express both NR1 and NR2 subunits. The NR1 
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subunit mRNA is found ubiquitously in the brain during development. Mutant mice 
defective in the NR1 subunit died shortly after birth and failed to develop 
whisker-related neuronal patterns in the trigeminal nuclei [32, 33]. At the embryonic 
stages, the NR2B subunit mRNA is expressed in the entire brain, and NR2D subunit 
mRNA is expressed in the diencephalons and brainstem [34]. After birth the NR2A 
subunit mRNA appears in the entire brain, and NR2C subunit mRNA mainly in the 
cerebellum. After birth, expression of NR2B subunit mRNA becomes restricted to the 
forebrain, and that of the NR2D subunit mRNA is strongly reduced. The NR2B subunit 
knockout mice died within 1 day after birth [35]; disruption of NR2A subunit of the 
mouse does not appreciably affect the growth and mating of the mice, but results in 
reduction of hippocampal LTP and spatial learning [36]; the NR2D subunit mice grow 
normally, but exhibit reduced spontaneous behavioral activity [37]; the deficiency of 
either the NR2A or NR2C subunit causes no remarkable behavioral abnormality, but the 
disruption of both NR2A and NR2C results in impairment of motor coordination[38]. 
Thus, multiple NR2 subunits are major determinants of the NMDA receptor channel 
diversity, and the molecular compositions and functional properties of NMDA receptor 
channel are different depending on the brain regions and developmental stages [39-41]. 
 
       Each subunit consists of extracellular N-terminal regulatory (R) domain, 
agonist binding (S) domain, channel forming domain and intracellular domain (Fig. 2). 
There are four membrane (M1-M4) regions in the channel forming domain, and second 
membrane segment (M2) is thought to form a re-entrant loop and contribute to the 
narrowest constriction of the channel (Fig. 2)[19]. The NMDA receptors are probably 
tetramers composed of two molecules each of NR1 and NR2 subunits [19, 42, 43 ]. 
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Fig. 2  Structure of NMDA receptor.  
Each NMDA receptor subunit contains two large extracellular regulatory domains 
(R-domain) and the agonist binding domains (S-domain). The transmembrane domain is 
comprised of M1-M3, and a re-entrant loop (M2). There is a intracellular C-terminal 
domain of each subunit. The receptor is gated by the co-agonist glutamate (Glu) and 
glycine (Gly). The NMDA receptor are probably heterotetramaers composed of two 
molecules each of NR1 and NR2 subunits. It indicates that some compounds bound to 
the R-domain of NMDA receptors. 
 
 
 6 
       The multiple effects of spermine on NMDA receptors are summarized in Fig. 3. 
spermine potentiates NMDA currents in the presence of saturating concentrations of 
glycine (glycine-independent stimulation; mechanism 1 in Fig.3), an effect that involves 
an increase in the frequency of channel opening and a decrease in the desensitization of 
NMDA receptors [12-14]. A second involves an increase in the desensitization of 
NMDA receptors for glycine (glycine-dependent stimulation; mechanism 2 in Fig. 3) 
[11-44].  
 
      In addition to stimulation, voltage-dependent inhibition by extracellular 
spermine was seen at native NMDA receptors (in the absence of extracellular Mg2＋) 
possibly representing a direct block of the ion channel by sperimine (mechanism 3 in 
Fig. 3) [11-13, 45, 46]. The strong voltage-dependent inhibition may be due to binding 
of spermine within the ion channel pore at a site close to, or overlapping with, the 
bingidng site for extracellular Mg2＋. There is no evidence to suggest that intracellularly, 
produces an incomplete block that probably reflects permeation of spermine through 
NMDA channels (Fig. 3) [11, 47].  
 
      Stimulation by spermine is dependent on the type of NR1 splice variant and the 
type of NR2 subunit present in NMDA receptors [10, 45, 48-51]. Only receptors 
expressed from splice variants such as NR1A, that lack a 21 amino acid insert encoded 
by exon 5 show glycine-independent stimulation by spremine [48, 49] Furthermore the 
various effect of spermine are differentially manifested in heteromeric NR1A/NR2 
receptors containing different NR2 subuints (Fig. 3)[10, 45, 51]. NMDA receptors are 
inhibited by protons, with a tonic inhibition of about 50% at physiological pH (7.3-7.5)  
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[52, 53]. Sensitivity to protons, like sensitivity to stimulation by spermine, is influenced 
by the presence of exon 5 in NR1. Variants that contain the insert (such as NR1B) are 
less sensitive to protons than are variats that lack the insert [54]. The 
glycine-independent form of spermine stimulation is influenced by extracellular pH.  
 
      Ifenprodil is a novel NMDA receptor antagonist that selectively inhibits 
NR1/NR2 receptors containing the NR2B subunit [55, 56]. Ifenprodil acts as a 
noncompetitive, partial, and voltage-independent antagonist [55, 57, 58]. Its potency 
strongly depends on the extracellular pH and is only weakly affected by the insertion of 
the NR1 exon 5 [59, 60]. Finally, ifenprodil displays use dependence such that binding 
of glutamate increase biding of ifenprodil and vice versa [61, 62]. 
       
      There are complex interaction between spermine, proton and ifenprodil at 
NMDA receptors. Spermine stimulation may involve relief of protein inhibition [54], 
whereas ifenprodil inhibition may involve an increase in proton inhibition [60]. Using 
site-directed mutagenesis, identified that a cluster of acidic residues located neat the 
exon 5 splice site influence senxitivity to spermine and pH, and also identified a several 
redidues in the proximal part of the amino terminus of NR1A that appear to form part of 
the ifenprodil binding site. This region, containing the biding sites for spermine and 
ifenprodil, may influence the downstream agonist binding domain S1 and S2 that 
constitue the glycine binding pocket. 
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Fig.3  Modulation of NMDA receptors.  
Diagram of NMDA receptor is showing effect of spermine ,and ifenprodil .Numbers 
indicfate various mavroscopic effects of these modulators . Spermine has 3 macroscopic 
effects that are differentially controlled by NR2 subunits. 
 
      Indeed, the structures of the agonist binding domains of several glutamate 
receptor subunits, including GluR0, GluR2, GluR5, NR1 and NR2A have been 
determined by X-ray crystallography, and these domains do indeed form bi-lobed 
“clamshell” structures similar to bacterial periplasmic binding proteins [68, 84, 72, 43, 
83] . The region of the amino terminus preceding S1 also has sequence similarity and a 
predicted structure similar to bacterial periplasmic binding proteins, in particular the 
leucine/isoleucine/valine binding protein (LIVBP) [64].  We have termed this region 
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the regulatory (R) domain.  Mutations at a number of residues in this region of the 
NR1 subunit affect spermine stimulation[64, 94].  This region has also been referred to 
as the “amino terminal domain” (ATD or NTD) and the “LIVBP-like domain” [73, 88, 
95]. We have suggested that a spermine binding site is located in or near the cleft of the 
R domain of the NR1 subunit [64].  
 
 Ifenprodil is an atypical NMDA antagonist that binds outside the ion channel 
pore and selectively inhibits NMDA receptors containing the NR2B subunit [55, 93]. .  
Inhibition by ifenprodil is pH-dependent and, mechanistically, may involve an increase 
in tonic proton inhibition  [59, 60].  Although it was initially suggested that ifenprodil 
is an antagonist at the stimulatory polyamine site, this does not seem to be the case.  
There is evidence that spermine and ifenprodil act at discrete sites with an allosteric 
interaction [77, 64]. Mutations at several residues in the R domain of NR1 greatly 
influenced ifenprodil inhibition, and we have suggested that this region may form part 
of the ifenprodil binding site [64].  It has also been reported that mutations at residues 
in the R domain of NR2B strongly affect ifenprodil inhibition [89], and it was proposed 
that the R domain of NR2B forms the ifenprodil binding site whereas the equivalent 
region of NR2A forms a high-affinity Zn2+ binding site, involving several amino acid 
residues equivalent to those found at the proposed ifenprodil site in NR2B [88, 89].   
 
 In this paper, we have studied binding of radiolabeled spermine and ifenprodil 
to purified soluble R domains of NR1, NR2A, and NR2B, to determine whether these 
ligands can bind to the isolated R domains and to determine the relationship between 
binding to the R domains and the effects at intact, functional receptors.  We found that 
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spermine binds to all three domains, but with the highest affinity at NR1-R.  Ifenprodil 
binds with high affinity to NR1-R and NR2B-R but not to NR2A-R. We also study the 
spermine and ifenprodil binding site in NMDA receptor through homology modeling of 
NR1A-R and NR2B-R. Through the simulation we found that there are two binding 
sites of spermine in NR1A-R and one is into the cleft of the 3D model of NR1A-R the 
other on the surface. But in the 3D model of NR2B-R there is only one spermine 
binding site. Ifenprodil bound into the cleft of the 3D model of NR2B-R and bound to 
surface of the3D model of NR 1A-R. The results suggest that the ligand which bound to 
the cleft of the NR-R maybe regulate the NMDA receptor more than to the surface. 
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Plasmids 
For production of COOH-terminal histidine-tagged R domain proteins, DNA 
fragments encoding NR1(19-380), NR2A(23-389) and NR2B(27-390) (numbering is 
from the initiator methionine, thus these constructs lack the signal peptide) were 
amplified by polymerase chain reaction (PCR) using primer pairs of 
(5’-TATACATATGCGCGCCGCCTGCCGACCC-3’ and 
5’-GGTGCTCGAGGATGATCTTCCTGTCAT-3’) for NR1, (5’-TATACATATGCA-
GAACGCGGCGGCG-3’ and 5’-GGTGCTCGAGGATGATCTTCCTGTCAT-3’) for 
NR2A and (5’-TAT-ACATATGCGTTCCCAAAAGAGC-3’ and 5’-CTCGAGTGC-
GGCCGCCACATAATACTTCATCTGCAG-3’) for NR2B.  The rat NR1A clone, 
which lacks the exon-5 insert [21], and rat NR2A and 2B clones [26] were used as 
templates.  The DNA fragments obtained by PCR were digested with NdeI and XhoI 
for NR1 and NR2A, and with NdeI and NotI for NR2B, and inserted into the same 
restriction sites of pET29b (Novagen) to construct plasmids pET29b-NR1(19-380), 
pET29b-NR2A(23-389) and pET29b-NR2B(27-390).  The PCR fragments were 
sequenced over the entire length of each fragment, and the sequences correspond to 
those in the NR subunit cDNAs. 
 
Purification of R domain proteins 
Escherichia coli BL21(DE3) (Novagen) cells carrying pET29b-NR1(19-380), 
pET29b-NR1A(19-380, E181Q), pET29b-NR2A(23-389) or pET29b-NR2B(27-390) 
were grown in 2 L of modified Luria-Bertani medium (10 g tryptone, 10 g yeast extract 
and 5 g NaCl per liter) containing 50 µg/ml kanamycin at 37 ˚C until A600 reached 0.3.  
Protein production was induced by 1 mM isopropyl-β-D-thiogalactopyranoside for 4 h.  
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Inclusion bodies were prepared using methods similar to those described by Chen and 
Gouaux (1997).  Cells were collected by centrifugation, washed once with 10 mM 
Tris-HCl, pH 8.0, containing 1 mM MgCl2, and suspended in 100 ml of 20% sucrose 
containing 30 mM Tris-HCl, pH 7.5, 10 mM EDTA and 0.1 mg/ml lysozyme.  Cells 
were kept on ice for 20 min, and spheroplasts were collected by centrifugation at 30,000 
g for 30 min.  Spheroplasts were resuspended in 200 ml of 50 mM Tris-HCl, pH 7.5, 
0.01% Triton X-100, 1 mM dithiothreitol (DTT) and 100 mM KCl, and sonicated for 2 
min using an Ultrasonic Disruptor UD201 (TOMY, Tokyo).  After treatment of the cell 
lysate with 20 µg/ml DNase I plus 10 mM MgCl2 (30 min on ice), inclusion bodies were 
collected by centrifugation at 30,000 g for 15 min.  Inclusion bodies were resuspended 
in 50 ml of buffer (20 mM Tris-HCl, pH 7.5, 6 M guanidine-HCl, 500 mM NaCl, and 5 
mM imidazole), kept on ice for 1 h, and centrifuged at 30,000 g for 15 min.  The 
supernatant contained about 70 mg protein, half of which (about 35 mg protein) was 
applied to each of two 5 ml of Ni-NTA columns (Qiagen).  After washing with buffer 
(20 mM Tris-HCl, pH 7.5, 6 M guanidine-HCl, 500 mM NaCl, and 20 mM imidazole), 
R domain proteins were eluted with an elution buffer (20 mM Tris-HCl, pH 7.5, 6 M 
guanidine-HCl, 500 mM NaCl, and 100 mM imidazole).   
 
 Proteins (100 μg/ml) were refolded through gradual decrease in the 
concentration of guanidine-HCl by stepwise dialysis against Buffer 1 [25 mM 
Hepes-KOH, pH 7.5, 100 mM KCl, 0.1 mM EDTA, 1 mM dithiothreitol, 10 µM E-64-C, 
a thiol protease inhibitor, 10 µM FUT-175, a serine protease inhibitor, 0.5 mM 
phenylmethylsulfonyl fluoride (PMSF), 10% glycerol and 0.01% Brij-35] containing 1 
M guanidine-HCl, Buffer 1 containing 0.5 M guanidine-HCl, Buffer 1 containing 0.2 M 
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guanidine-HCl, and Buffer 1 at 4 ˚C for at least 4 h each.  R domain proteins were 
concentrated to approximately 1 mg/ml by ultrafiltration using PM10 filter (Amicon), 
and precipitates were removed by centrifugation.  Protein concentration was 
determined by the method of Lowry et al. (1951).  About 20 mg of R domain protein 
was obtained from a 2 liter culture.  Monomers of the three R domain proteins (41.6 
kDa of NR1-R, 42.3 kDa of NR2A-R and 42.7 kDa of NR2B-R) were isolated by gel 
filtration using TSK gel G3000SW (2.15 x 67.5 cm) (TOSOH) and Buffer 2 containing 
20 mM Tris-HCl, pH 7.5, 0.15 M NaCl, 1 mM dithiothreitol, and 0.01% Brij-35.  
Monomers of R domains were eluted at an elution volume of 132 to 152 ml.  The 
protein was concentrated to approximately 2 mg/ml by ultrafiltration using PM10 filter 
(Amicon), and used for the experiments.  The percentage of monomer and dimer of 
NR1-R, NR2A-R and NR2B-R during the assay was confirmed by gel filtration using 
TSK gel G3000SW (0.75 x 30 cm) (TOSOH) and Buffer 2.  As a molecular marker, 
phosphorylase B (94 kDa), ovalbumin (45 kDa) and lysozyme (14.5 kDa) were used. 
 
Binding of spermine and ifenprodil to R domain proteins 
Binding assays were carried out as described previously [66].  The reaction 
mixture (0.5 ml) containing 50 to 100 µg R-domain proteins, 10 mM Tris-HCl, pH 7.5, 
and 50 mM KCl was preincubated at 30 ˚C for 10 min, and [14C]spermine (463 
MBq/mmol, Amersham) or [3H]ifenprodil (15 GBq/mmol, PerkinElmer) was added at 5 
to 250 µM for spermine and 0.05 to 0.8 µM for ifenprodil.  After incubation at 30 ˚C 
for 20 min, the reaction was stopped by addition of 2 ml cold Buffer (10 mM Tris-HCl, 
pH 7.5, and 50 mM KCl) and the protein was collected on HAWP02400 filter (0.45 µm, 
Millipore).  After the filter was washed 2 times with 2 ml of cold Buffer, radioactivity 
 15 
on the filter was measured by a liquid scintillation spectrometer.  Blank value (the 
level of [14C]spermine or [3H]ifenprodil bound to NR1-R, NR2A-R and NR2B-R in the 
reaction mixture kept at 0 ºC) was subtracted from total radioactivity to obtain specific 
binding.  The dissociation constant (Kd) and maximum binding activity (Bmax) were 
calculated from Scatchard plots as described previously [76]. The k1 and k-1 values were 
calculated with GraphPad Prism V. 4 (GraphPad software).   
 
Determination of the Kd values of spermine and ifenprodil for NR1-R, NR2A-R 
and NR2B-R by CD (circular dichroism) measurements 
The CD measurements were performed at 25 ºC using a J-820 
spectropolarimeter (Jasco International Co) equipped with a 1.0-mm path-length cuvette.  
The samples were scanned from 190 to 250 nm and accumulated 10 times at a 
resolution of 0.1 nm with a scanning speed of 50 nm/min and sensitivity of 200 mdeg.  
All of the CD data are expressed as molar ellipticity.  The concentration of NR1-R, 
NR2A-R and NR2B-R used was 0.3-, 0.5- and 0.5 mg/ml, respectively.  The buffer 
used was the same as that used for binding assay of spermine and ifenprodil.  
Increasing amounts of spermine or ifenprodil were added in small aliquots from stock 
solutions to 300 μl of protein solution and were allowed to bind for 5 min at room 
temperature.  The CD spectra of the protein in the absence and presence of increasing 
concentrations of spermine (5 - 360 μM) or ifenprodil (0.05 - 2 μM) were recorded.  In 
this experiment, ifenprodil hemitartrate was used instead of ifenprodil to avoid the 
precipitation of proteins.  The final change of assay volume was < 3%.  The Kd 
values were determined according to the double-reciprocal equation plot shown in the 
figure. 
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NMDA conloes and site-directed mutagenesis 
        The NR1 clone used in these studies is the NR1A variant [21], which lacks the 
21-amino acid insert encoded by exon 5. This clone was gifts from Dr. S. Nakanishi 
(Osaka Bioscience Institute, Osaka, Japan). The wild type mouse and rat NR2B 
clones[26,29] were gifts from Drs. M. Mishina (Graduate School of medicine, 
University of Tokyo, Tokyo, Japan) and P. H. Seeburg (Center for molecular biology, 
University of Heidelberg, Heidelberg, Germany). The preparation of most other NR1 
and NR2B mutats has been described previously [64, 65, 67,]. Site-directed mutagenesis 
to construct new NR1 and NR2B mutant was carried out by the method of Ho et 
al.(1987) using the polymerase chain reaction, with Pfu polymerase purchased from 
Stratagene. Amino acids are numbered from the initiator methione in each subunit. 
Mutations were confirmed by DNA sequending using a Seq 4´4 personal sequencing 
system (Amersham Biosciences) over approximately 300 nuculeotides cotaining the 
mutation. Amino acids are numbered from the initiator methione in NR1 and NR2B 
clones.  
 
Preparation of oocytes and voltage clamp recording 
Adult female Xenopus laevis (Saitama Experimental Animals Supply Co. Ltd., 
Saitama, Japan) were chilled on ice, and the preparation and maintenance of oocytes 
were carried out using the methods similar to those described previously [55].  Capped 
cRNAs were prepared from linearized cDNA templates using mMessage mMachine kits 
(Ambion).  Oocytes were injected with NR1 and NR2 cRNAs in a ratio of 1:5 (0.2 - 4 
ng of NR1 plus 1 - 20 ng of NR2).  Macroscopic currents were recorded with a 
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two-electrode voltage-clamp using Dual Electrode Voltage Clamp Amplifier CEZ-1250 
(Nihon Koden, Tokyo).  Electrodes were filled with 3 M KCl.  Oocytes were 
continuously superfused (ca. 5 ml/min) with a Mg2+-free saline solution (96 mM NaCl, 
2 mM KCl, 1.8 mM BaCl2, 10 mM HEPES, pH 7.5).  This solution contained BaCl2 
rather than CaCl2, and in most experiments oocytes were injected with 
K+-1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA) (100 nl; 40 
mM, pH 7.0) on the day of recording to eliminate Ca2+-activated Cl- currents [55].  
Oocytes were voltage-clamped at a holding potential of –20 mV.  Data were recorded 
by using a Digidata 1322A interface with software pCLAMP8 for Windows (Axon 
Instruments, USA).  Receptors were activated by superfusion of glutamate and glycine 
(10 mM). 
        Data analysis and cureve fitting were carried out using Axongraph (Molecular 
Devices) or SigmaPlot (SPSS Inc., Chicago, IL).  
 
Identification of heterodimer formation of R domain by immunoprecipitation and 
Western blot analysis 
The reaction mixture (0.3 ml) containing either 45 μg NR1-R, 30 μg NR2A-R, 
30 μg NR2B-R, 45 μg NR1-R plus 30 μg NR2A-R or 45 μg NR1-R plus 30 μg NR2B-R, 
10 mM Tris-HCl, pH 7.5, 50 mM KCl, and 2 μg of anti-NR1 (sc-9058, Santa Cruz) was 
kept at 4 °C for 2 h.  Then, antibody-coupled protein was precipitated by addition of 2 
μl PANSORBIN® Cells (CALBIOCHEM) and incubation at 4 °C for 2 h.  The 
precipitate was collected by centrifugation at 30,000 g for 5 min, washed 3 times with 
Buffer 3 [0.5 M Na-phosphate buffer, pH 7.5, 100 mM NaCl, 1% Triton-X100 and 0.1% 
sodium dodecyl sulfate (SDS)], and boiled for 5 min in SDS-PAGE sample buffer.  
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Western blotting was performed by the method of Nielsen et al. (1982) using 3 μg 
protein and ECL Western blotting reagents (GE Healthcare).  NR1-R, NR2A-R and 
NR2B-R were detected with anti-NR1, anti-NR2A (sc-9056, Santa Cruz), and 
anti-NR2B (sc-9057, Santa Cruz).  These commercially available antibodies were 
raised against epitopes in the first 70 to 300 amino acids of the amino terminus (i.e., the 
R domain) of each subunit.   
 
Homology modeling of NR1 and NR2B regulatory domain of NMDA receptor and 
docking of spermine and ifenprodil 
Three dimensional structures of NR1A-R and NR2B-R were constructed by 
homology modeling with the Amber99 force field in MOE (version 2007.09, CCG Inc., 
Montreal, Canada) based on the Brookhaven Protein Databank 1EWK. Furthermore, the 
structure of the docking complex between NR1A-R and spermine, NR1A-R and 
ifenprodil, NR2B-R and spermine, and NR2B-R and ifenprodil were predicted with 
ASEDock of MOE. The resulting three-dimensional structure of each complex was 
displayed using MolFeat (Ver. 3.6, FiatLux, Tokyo, Japan). 
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Introduction 
The binding of spermine and ifenprodil to the amino terminal regulatory (R) 
domain of the N-methyl-D-aspartate receptor was studied using purified regulatory 
domains of the NR1, NR2A and NR2B subunits, termed NR1-R, NR2A-R and NR2B-R.  
The R domains were overexpressed in Escherichia coli and purified to near 
homogeneity.  The Kd values for binding of [14C]spermine to NR1-R, NR2A-R and 
NR2B-R were 19, 140 and 33 µM, respectively.  [3H]Ifenprodil bound to NR1-R (Kd, 
0.18 µM) and NR2B-R (Kd, 0.21 µM), but not to NR2A-R at the concentrations tested 
(i.e. 0.1 to 0.8 μM).  These Kd values were confirmed by circular dichroism 
measurements.  The Kd values reflected their effective concentrations at intact 
NR1/NR2A and NR1/NR2B receptors.  The results suggest that effects of spermine 
and ifenprodil on NMDA receptors occur through their binding to the regulatory 
domains of the NR1, NR2A and NR2B subunits.  The binding capacity of spermine or 
ifenprodil to a mixture of NR1-R and NR2A-R or NR1-R and NR2B-R was additive 
with that of each individual R domain.  Binding of spermine to NR1-R and NR2B-R 
was not inhibited by ifenprodil and vice versa, indicating that the binding sites for 
spermine and ifenprodil on NR1-R and NR2B-R are distinct. 
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Results 
Purification of R domain proteins 
The regulatory (R) domains of native NMDA receptor subunits are in the 
extracellular environment, as is the S1-S2 agonist-binding domain (Fig. 4a), and we 
reasoned that the R domains could be expressed and purified as soluble proteins, as has 
been reported for S1-S2 fusion proteins from several glutamate receptors [69, 68, 84, 72, 
43, 83].  The R domains of NR1, NR2A, and NR2B, comprising the first 360 to 370 
amino acids after the signal peptide (Fig. 4b) were subcloned into pET29b with a 
histidine tag at their COOH-terminus.  These R domain proteins were expressed 
separately in E. coli, purified from inclusion bodies using Ni-NTA column 
chromatography, and refolded by dialysis.  As shown in Fig. 4c, the soluble NR1-R, 
NR2A-R and NR2B-R proteins were purified to near homogeneity.  The molecular 
mass of these proteins on SDS-PAGE is similar to that predicted based on their amino 
acid sequences (41.6 kDa of NR1-R, 42.3 kDa of NR2A-R and 42.7 kDa of NR2B-R), 
although the mobility of NR2A-R was slightly greater than that of NR1-R and NR2B-R.  
In Fig. 4d, the molecular size of these purified R domains in solution is shown.  
NR2A-R and NR2B-R mainly consisted of monomer and dimer forms, but NR1-R 
contained a polymerized form together with monomers and dimers. The percentage of 
the monomer form of NR1-R, NR2A-R and NR2B-R was 37, 73 and 71%, respectively.  
The elution profile of NR1-R, NR2A-R and NR2B-R was not influenced by adding 0.1 
mM spermine to the elution buffer, suggesting that spermine is not involved in 
polymerization or dimerization of each regulatory domain (data not shown).  These 
preparations were used for subsequent binding assays. 
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Fig. 4  Structure and purity of R domain proteins.  (a) Schematic of an NMDA receptor 
subunit showing the extracellular R and S1-S2 domains, three membrane-spanning domains (M1, 
M3, M4), a re-entrant loop (M2) and intracellular C terminus.  (b) Schematics of NR1, NR2A, and 
NR2B subunits showing the positions of the signal peptides (sp), the R domains used in this study, 
the S1 and S2 domains, and the membrane spanning and re-entrant loops (M1-M4).  Amino acids 
are numbered (above each schematic) from the initiator methionine.  (c) Sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis of purified R domains (NR1-R, NR2A-R and NR2B-R).  
Each lane of the 12% acrylamide gel contained 2 µg protein, and the gel was stained with Coomassie 
Brilliant Blue R250.  Numbers on the left represent molecular mass in kDa.  (d) Gel filtration of 
purified R domain proteins used for radioligand binding assays.  The pattern indicates the extent of 
dimerization and polymerization after the isolation and concentration of the monomer fraction of R 
domain proteins.  Peaks corresponding to monomers are indicated by an arrow in each panel.   
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Binding of spermine and ifenprodil to R domain proteins 
Binding of [14C]spermine to the soluble R domain proteins was determined.  
The binding of spermine to NR1-R, NR2A-R and NR2B-R was saturable (Fig. 5, upper 
panels), and the Kd values for spermine at these regulatory domains were 19, 140 and 
33 µM, respectively (Fig. 5, lower panels).  Thus, although spermine can bind to all 
three R domains, it binds with highest affinity to NR1-R.  Bmax values, which indicate 
proportion of active protein, for NR1-R, NR2A-R, and NR2B-R were 6.3, 6.9 and 7.3 
nmol/mg R domain protein, which were equivalent to 0.24, 0.29 and 0.32 mol/mol R 
domain, respectively.  Judging from the percentage of monomer and dimer (Fig. 4d) 
and Bmax values for spermine binding (Fig. 5b), spermine may bind to both monomer 
and dimer forms of NR1-R, NR2A-R and NR2B-R.  The Hill coefficient of spermine 
binding to these three R domains was almost 1.0, suggesting that spermine binding to 
each R domain is independent, even though dimers can be formed.  As a control, 
binding of spermine was studied using an unrelated protein, ovalbumin, and a mutant of 
NR1-R, E181Q, which drastically reduces spermine stimulation as studied in functional 
assays [64].  There was little binding of spermine to ovalbumin, and binding to the 
E181Q mutant was reduced compared to the wild-type NR1-R domain (Fig. 5).  The 
Kd value of spermine at the E181Q mutant was 74 μM compared with 19 μM for wild 
type NR1-R.  Such a decrease in spermine binding to the E181Q mutant was nearly 
parallel with the decrease in spermine stimulation in functional assays [64].  This is 
consistent with the proposal that residue E181 forms part of the spermine binding site 
on NR1.  
 
 24 
 The Kd value for binding of spermine to the NR2B R domain was also 
calculated by determining the association (k1) and dissociation (k-1) rate constants from 
studies of the time course of association and dissociation of [14C]spermine (Fig. 6). 
Values of k1 were obtained using spermine concentrations of 12.5–100 μM, and values 
of k-1 were obtained from dissociation plots after addition of non-labeled 3 mM 
spermine. Under these conditions, the association rate was not fully 
concentration-dependent. The Kd value was calculated as the average using values of k1 
and k-1 at concentrations of 12.5, 25, and 50 μM [14C]spermine. The values for k1 and k-1 
were 8500 M-1 min-1 and 0.22 min-1, respectively. Accordingly, the Kd was determined 
to be as 25.9 μM, which is similar to the Kd measured in the stauration binding analysis 
shown in Fig. 5.  
 
 We then measured the effects of spermine on recombinant NMDA receptors 
expressed in oocytes to compare the concentration of spermine required to potentiate 
intact, functional NMDA receptors with the effects of spermine seen at isolated R 
domains.  Since spermine stimulation is seen at both NR1/NR2A and NR1/NR2B 
receptors in the presence of 10 μM glutamate and 1 μM glycine at pH 7.5 [9], the EC50 
values for spermine were measured under these conditions. To minimize 
voltage-dependent block by spermine, oocytes were voltage-clamped at -20 mV.  As 
shown in Fig. 7, the EC50 values for spermine stimulation at NR1/N2A and NR1/NR2B 
receptors were 278 µM and 78 µM, respectively.  The ratio of EC50 values at NR2A 
versus NR2B correlates well with the Kd values for spermine binding, although EC50 
values are higher than Kd values.  
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 Binding of [3H]ifenprodil to the purified R domain proteins was also studied.  
Ifenprodil bound to NR1-R and NR2B-R, but there was no specific binding of 0.1 to 0.8 
µM [3H]ifenprodil to NR2A-R.  As shown in Fig. 8, binding of ifenprodil to NR1-R 
and NR2B-R was saturable, with Kd values of 0.18 µM and 0.21 µM, respectively.  
These values were close to the IC50 (0.34 μM) of ifenprodil at NR1/NR2B [55].  Bmax 
values for both NR1-R and NR2B-R were 5.6 and 5.2 nmol/mg R domain protein, 
which were equivalent to 0.24 and 0.21 mol/mol R domain protein, respectively.  
These values were similar to the binding capacity for spermine at these proteins.  Hill 
coefficient for ifenprodil binding to NR1-R and NR2B-R was almost 1.0, suggesting 
that ifenprodil binding on each R domain is independent, even though homodimers can 
be formed, and that there is likely one binding site per R domain.   
 
 The binding of spermine and ifenprodil to R domain proteins was also 
measured by CD.  The CD spectra of R domain proteins were analyzed from 190 to 
250 nm with increasing concentrations of spermine or ifenprodil, and the shifts of 
magnitude at wavelength 208.6 nm reflecting a-helical structure were plotted.  As 
shown in Figs. 9 and 10, the Kd values of spermine for NR1-R, NR2A-R and NR2B-R 
were 20, 133 and 35 μM, respectively, and those for ifenprodil at NR1-R and NR2B-R 
were 0.14 and 0.17 μM, respectively.  There was no change in the CD spectra of 
NR2A-R by 2 μM ifenprodil.  The results are similar to those seen in studies with 
radiolabeled spermine and ifenprodil and confirm that their binding to NR1-R, NR2A-R 
and NR2B-R is saturable and specific. 
 
 To determine whether the binding sites for spermine and ifenprodil on 
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individual NR1 and NR2 R domains are altered through an interaction with the R 
domains of the other subunits, the binding of spermine and ifenprodil was compared 
using NR1-R only, NR2-R only and a mixture of NR1-R and NR2-R.  These 
experiments were carried out using 20 µM spermine and 0.2 µM ifenprodil.  As shown 
in Fig. 11, the binding of spermine and ifenprodil was quantitative, being dependent on 
the amount of R domain protein (50 to 100 µg).  Furthermore, binding of either ligand 
to NR1-R and NR2A-R or NR2B-R was simply additive.  We also carried out 
experiments to confirm that heterodimers of NR1-R + NR2A-R and NR1-R + NR2B-R 
do indeed form in solution under these conditions.  This was done by 
immunoprecipitation with an anti-NR1-R antibody followed by Western blotting with 
anti-NR1 or anti-NR2 antibodies (Fig. 12).  Although NR2A-R and NR2B-R were not 
immunoprecipitated by anti-NR1, these two R domains were coimmunoprecipitated 
with NR1-R by anti-NR1, indicating that heterodimer formation between NR1-R and 
NR2A-R or NR2B-R does indeed occur after the individual NR1 and NR2 R domains 
are added together in solution.  The percentage of heterodimer formation was 
estimated to be 20 to 40%, which was similar to the percentage of homodimer formation 
(see Fig. 4).  The results suggest that spermine and ifenprodil bind independently to 
each regulatory domain, even when dimer formation occurs.  The results are in 
accordance with the data showing Hill coefficients of unity for binding of spermine and 
ifenprodil to NR1-R and NR2-R (Figs. 5 and 8). 
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Fig. 5  Binding of spermine to R domain proteins.   
Saturation isotherms (upper panels) and Scatchard plots (lower panels) of the binding of 
[14C]spermine to NR1-R (a), NR2A-R (b), and NR2B-R (c).  The Hill coefficient was 
calculated from the plot of the logarithmic form of a Hill equation.  Binding of 
[14C]spermine to NR1-R (E181Q) and that to ovalbumin was also shown in upper 
figures of (a) and (b), respectively.  Values are means ± S. D. from three experiments.  
SPM, spermine.   
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Fig. 6  Time course of [14C]spermine binding to NR2B-R and its dissociation by 
nonlabeled 3 mM spermine.   
The binding assay was performed using 12.5 (), 25 (), 50 () and 100 () μM 
[14C]spermine as substrate, and nonlableled 3 mM spermine was added to the reaction 
mixture at 16 min after the onset of incubation.  [14C]spermine bound to NR2B-R was 
measured as described in Materials and methods.  Values are means ± S. D. from three 
experiments. 
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Fig. 7  Effects of spermine at intact, functional NMDA receptors.   
The effects of spermine on currents induced by glutamate and glycine at NR1/NR2A (○) 
and NR1/NR2B (●) were measured in oocytes expressing recombinant receptors and 
voltage clamped at –20 mV.  Values are mean ± S. D. from five experiments.  The 
Hill coefficients for spermine at NR1/NR2A and NR1/NR2B were 1.17 and 1.05, 
respectively.  
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Fig. 8  Binding of ifenprodil to NR1-R and NR2-R.  
Saturation isotherms (upper panels) and Scatchard plots (lower panels) of the binding of 
[3H]ifenprodil to NR1-R (a) and NR2B-R (b).  The Hill coefficient was calculated 
from the plot of the logarithmic form of a Hill equation.  Binding of [3H]ifenprodil to 
NR2A-R is also shown in upper figure of (b).  Values are means ± S. D. from three 
experiments.   
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Fig. 9  Measurement of the Kd values for spermine at NR1-R, NR2A-R and 
NR2B-R by CD.  
CD measurements were performed as described in Materials and methods.  
Concentration-dependent effects of spermine on shifts of magnitude at 208.6 nm are 
shown in the upper panels, and the Kd values of spermine were determined from 
double-reciprocal plots as shown in the lower panels.  Values are mean ± S. D. from 
three experiments. 
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Fig. 10  Measurement of the Kd values of ifenprodil for NR1-R, and NR2B-R by 
CD.   
CD measurements were performed as described in Materials and methods. 
Concentration-dependent effects of ifenprodil on shifts of magnitude at 208.6 nm are 
shown in the upper panels, and the Kd values of ifenprodil were determined from 
double-reciprocal plots as shown in the lower panels.  Values are mean ± S. D. from 
three experiments. 
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Fig. 11  Binding of spermine and ifenprodil to various combinations of R domain 
proteins.  
Binding was measured using 50 to 100 µg of NR1-R NR2A-R or NR2B-R, alone or in 
combination.  The concentrations of [14C]spermine and [3H]ifenprodil were 20 µM and 
0.2 µM, respectively.  Values are means ± S. D. from three experiments. 
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Fig.12 Identification of heteromer formation of R domains by 
immunoprecipitation followed by Western blot analysis.  
The R domains shown in the figure were immunoprecipitated by anti-NR1 as described 
in Materials and methods.  Immunoprecipitated protein was detected by Western blot 
analysis using anti-NR1, anti-NR2A and anti-NR2B.  Experiments were repeated twice, 
and essentially the same results were obtained.   
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Distinct binding sites for spermine and ifenprodil on NR1-R and NR2B-R   
Experiments were carried out to determine if there are interactions between 
spermine and ifenprodil on the purified NR1-R protein.  As shown in Table 1, binding 
of spermine to NR1-R was inhibited by nonlabeled spermine and spermidine, but not by 
tribenzylspermidine (TB-34), a polyamine derivative that is a potent NMDA channel 
blocker but does not have effects at the stimulatory polyamine site [74]. Binding was 
also unaffected by agonists (glycine and glutamate) that bind in the S1-S2 domains, and 
by ifenprodil.  The binding of ifenprodil to NR1-R was inhibited by nonlabeled 
ifenprodil, but not by agonists or by spermine and spermidine (Table 1).  Similarly, the 
binding of spermine to NR2B-R was inhibited by nonlabeled spermine and spermidine, 
but not by agonists and ifenprodil, and that of ifenprodil was inhibited by nonlabeled 
ifenprodil, but not by agonists and spermine and spermidine (Table 2).  The results 
indicate that spermine and ifenprodil bind to distinct sites on NR1-R and NR2B-R. 
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Table 1  Spermine and ifenprodil binding to purified NR1-R 
 
 
[14C]Spermine bound [3H]Ifenprodil bound 
Addition 
nmol/mg protein % nmol/mg protein % 
None 
Spermine (300 µM) 
Spermidine (1 mM) 
Tribenzylspermidine (100 µM) 
Ifenprodil (10 µM) 
Glycine (100 µM) 
Glutamate (100 µM) 
3.20 
0.08 
0.09 
3.28 
2.83 
3.23 
3.45 
± 
± 
± 
± 
± 
± 
± 
0.23 
0.01 
0.02 
0.21 
0.25 
0.24 
0.27 
100 
3 
3 
103 
88 
101 
108 
2.98 
2.63 
2.71 
 
0.27 
3.15 
2.88 
± 
± 
± 
 
± 
± 
± 
0.17 
0.14 
0.17 
 
0.01 
0.16 
0.19 
100 
88 
91 
n.d. 
9 
106 
97 
 
 
The concentration of [14C]spermine and [3H]ifenprodil used for the binding assay was 
20 µM and 0.2 µM, respectively.  Where indicated, nonlabeled spermine (300 µM), 
spermidine (1 mM), tribenzylspermidine (100 µM), ifenprodil (10 µM), glycine (100 
µM) or glutamate (100 µM) was added to the reaction mixture. Data are shown as mean 
± S. E. from three experiments.  n.d., not determined 
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Table 2  Spermine and ifenprodil binding to purified NR2B-R 
 
 
[14C]Spermine bound [3H]Ifenprodil bound 
Addition 
nmol/mg protein % nmol/mg protein % 
None 
Spermine (300 µM) 
Spermidine (1 mM) 
Ifenprodil (10 µM) 
Glycine (200 μM) 
Glutamate (200 μM) 
3.85 
0.28 
0.25 
4.14 
3.89 
3.93 
± 
± 
± 
± 
± 
± 
0.38 
0.05 
0.04 
0.36 
0.41 
0.40 
100 
7 
6 
108 
101 
102 
3.21 
3.17 
3.15 
0.48 
3.27 
3.31 
± 
± 
± 
± 
± 
± 
0.22 
0.40 
0.31 
0.09 
0.32 
0.34 
100 
99 
98 
15 
102 
103 
 
 
The concentration of [14C]spermine and [3H]ifenprodil used for the binding assay was 
40 µM and 0.4 µM, respectively.  Where indicated, nonlabeled spermine (300 µM), 
spermidine (1 mM), ifenprodil (10 µM) glycine (200 μM) or glutamate (200 μM) was 
added to the reaction mixture.  Data are shown as mean ± S. E. from three 
experiments. 
 
 
 
 
 
 38 
 
Effect of aminoglycosides on spermine binding to R domain proteins   
We have previously shown that a number of aminoglycosides potentiate 
macroscopic currents at heteromeric NR1/NR2B receptors, probably through binding to 
a stimulatory polyamine site on the receptor [82].  As shown in Fig. 13, binding of 
spermine to NR1-R, NR2A-R and NR2B-R was inhibited by neomycin B, 
paromomycin, kanamycin A and streptomycin, consistent with the idea that 
aminoglycosides act at the stimulatory polyamine binding sites on the R domains of 
NR1, NR2A and NR2B.  The magnitude of inhibition of spermine binding to R 
domain proteins by aminoglycosides paralleled potentiation of intact NR1/NR2B 
receptors by aminoglycosides measured in functional studies, and occurred at similar 
concentrations of aminoglycosides [82].   
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Fig. 13  Effect of aminoglycosides on spermine binding to R domain proteins.  
Binding of [14C]spermine was measured in the presence and absence of 
aminoglycosides (75 to 300 µM) as described in Materials and methods.  
[14C]Spermine used was 20 µM.  Values are means ± S. D. from three experiments. 
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Discussion 
Several studies have reported the purification and properties of soluble S1-S2 
domains of AMPA and kainate receptor proteins [69, 71]. The same approach has been 
applied to NMDA receptor subunits.  The characteristics of the glycine binding site on 
the NR1 subunit have been reported from studies using a purified soluble S1-S2 domain 
[75] and a membrane-bound fusion protein containing the entire extracellular portion (R 
domain plus S1-S2) of NR1 [86]. In more recent studies, some characteristics of an 
ifenprodil binding site on NR2B have been described using a purified soluble NR2B R 
domain [89, 95]. We have used a similar approach to study the binding sites for 
spermine and ifenprodil on the R domains of NR1 and NR2 subunits.  These studies 
indicate that spermine and ifenprodil can differentially bind to these domains.  The 
experiments led to several interesting findings as discussed below.   
 
 We found that spermine bound to the R domains of all three NMDA receptor 
subunits.  The affinity for spermine was NR1-R > NR2B-R > NR2A-R; the Kd values 
for spermine at NR1-R, NR2A-R and NR2B-R were 19, 140 and 33 μM, respectively.  
The results suggest that spermine stimulation of NR1/NR2A and NR1/NR2B may be 
caused through spermine binding to the R domain of NR2A and NR2B together with 
binding to the R domain of NR1.  It is notable that the potency of spermine as 
determined in functional assays was 3- to 4-fold lower at NR1/NR2A receptors (EC50, 
278 µM) than at NR1/NR2B receptors (EC50, 78 µM), which correlates with the 4-fold 
lower affinity for spermine of the NR2A R domain (Kd, 140 µM) compared to the 
NR2B R domain (Kd, 33 µM).  In any event, the results indicate that there are discrete 
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spermine binding sites on the three different R domain proteins, and are consistent with 
our previous mutagenesis studies that identified residues important for spermine 
stimulation in the R domains of NR1 and NR2B [63,64].   
 
 The results demonstrate that ifenprodil binds to NR1-R and NR2B-R, but not 
to NR2A-R.  It has been reported that mutations at several residues in NR2B-R greatly 
reduced sensitivity to ifenprodil [89]. These residues were in positions analogous to 
residues in the NR2A subunit that affect sensitivity to Zn2+ and may form a Zn2+ binding 
site on NR2A[94].  In the same report, ifenprodil was shown to retard protease 
digestion of a soluble NR2B-R domain (residues 28 to 375) but not of an NR2A R 
domain [89]. It was concluded that ifenprodil binds within the cleft of the bi-lobed R 
domain of NR2B, analogous to binding of Zn2+ in the cleft of the NR2A R domain [89].  
In this context, it should be noted that NR2A-R moves more rapidly on an SDS 
polyacrylamide gel compared with NR1-R and NR2B-R (see Fig. 4), even though the 
molecular masses of three regulatory domains were almost identical.  This suggests 
that the overall structure of NR2A-R may be different from that of NR1-R and NR2B-R, 
accounting for differences in the binding sites for Zn2+ and ifenprodil even though these 
two apparent binding sites share many homologous residues in NR2A and NR2B [88, 
89]. 
 
In the present study, we observed binding of [3H]ifenprodil to NR1-R and 
NR2B-R but not to NR2A-R. The Kd values for binding of ifenprodil to NR1-R and 
NR2B-R (0.18 and 0.21 μM, respectively) were similar to the IC50 for ifenprodil 
inhibition at intact, functional NR1/NR2B receptors (0.34 μM at pH 7.6) [55]. It has 
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also been reported that the binding constant for ifenprodil at NR2B-R was 
0.13–0.17 μM when measured by circular dichroism [95] , a finding that we also 
replicated in the current study. The finding that [3H]ifenprodil binds to NR1-R is 
consistent with our previous finding that mutations in this region of the NR1 subunit 
affect sensitivity to ifenprodil [64]. Although other reports have localized an ifenprodil 
binding site to NR2B-R [89], our results suggest that the R domain of NR1 is also 
capable of forming an ifenprodil binding site with a high affinity, similar to NR2B-R. 
The finding that ifenprodil can bind to the R domain of NR1 is consistent with the high 
affinity inhibition by ifenprodil of apparent "homomeric" NR1 receptors expressed in 
oocytes [55]. It has been proposed that these receptors are not truly NR1 homomers and 
that an endogenous 'NR2-like'Xenopus subunit can combine with NR1 to form these 
receptors [100]. However, another study [101] has convincingly shown that this 
endogenous subunit does not contribute to the formation of 'homomeric' NR1 receptors 
in Xenopus oocytes, and the true nature of such receptors (NR1 homomers or NR1/NRX 
heteromers) remains unresolved. There is no evidence for expression of functional 
homomeric NR1 receptors in vivo, and ifenprodil appears to produce high affinity 
inhibition (Kd less than 1 μM) only at heteromeric NR1/NR2 receptors containing 
NR2B. Thus, even though the NR1 R domain is capable of forming a high affinity 
ifenprodil binding site, the affinity for ifenprodil or the coupling of binding to channel 
activity may be reduced in heteromeric receptors containing NR2A, NR2C, and NR2D, 
but retained in receptors containing NR2B. 
The results from this study are consistent with the idea that spermine and 
ifenprodil act at distinct binding sites on the NMDA receptor [77, 64].  Amino acid 
residues involved in ifenprodil inhibition in NR1-R and NR2B-R were mainly located 
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between residues 80 and 200[64, 89]. On the other hand, amino acid residues that 
influence spermine stimulation in NR1 and NR2B were mainly located between 
residues 170 and 350 [63, 64]. It may be that spermine binds within the cleft of the R 
domain similar to polyamine binding to the bacterial protein PotD [90, 64]. In that case, 
ifenprodil may bind to another site within the cleft [89] or elsewhere on the R domain. 
Even though spermine and ifenprodil have separate binding sites, there are interactions 
(presumably allosteric) between these two ligands at intact receptors [77]. 
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Introduction 
        NMDA receptor function is modulated by a wide variety of compounds such 
as polyamine, proton and ifenprodil, and findings show that the biding sites for these 
modulators are found in the amino teminal domain of such receptors. In our previously 
studies suggest that the biding sites of spermine and ifenprodil are on the R domain of 
NMDA receptor. The R domain of NMDA receptors have not been crystallized but it 
has been noted that there is homology with other periplasmic binding proteins (LIVBP), 
polyamine binding protein (Pot D) and metabotropic glutamate receptors (mGluRs). In 
the present study, the construction of a three-dimensional model of the NR1A-R and 
NR2B-R is described using the closed agonist-binding domain of mGluR1 and docking 
the R domain with spermine and ifenprodil. Through the simulation we found that there 
are two binding sites of spermine in NR1A-R and one is into the cleft of the 3D model 
of NR1A-R the other on the surface. But in the 3D model of NR2B-R there is only one 
spermine binding site. Ifenprodil bound into the cleft of the 3D model of NR2B-R and 
bound to surface of the3D model of NR 1A-R. The results suggest that the ligand which 
bound to the cleft of the NR-R maybe regulate the NMDA receptor more than to the 
surface. 
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Results 
Determination of amino acid residues at the R domain of NR1A and NR2B which 
are involved in spermine stimulation at -20mV 
       Spermine is polycationic and we hypothesized that the amino groups of 
spermine may interact with acidic residues on NMDA receptor subunits, as has been 
found for the interaction of polyamines with the bacterial polyamine binding protein 
PotD[64]. We previously found that mutations at NR1 (E181) and NR1 (E342) 
influence spermine stimulation. In this study we made a series of individual point 
mutations in the R domain of NR1A and NR2B. We screen each mutation by measuring 
spermine stimulation at -20mV with 100 mM spermine [63, 64]. If spermine stimulation 
decreased³20% in the mutants compared with those of wild type NMDA receptor, it is 
judged that mutant amino acid residues are involved in spermine stimulation, 
respectively. 
 
      Results on NR1A and NR2B mutants are shown in Fig. 14 and 16. Mutations at 
the acidic residues of NR1A near NR1 (E181) and NR1 (E342) have a strong effect on 
spermine stimulation. It suggests that there are two spermine binding sites in NR1A-R. 
Mutation at acidic residues from 190-210 of NR2B show a strong effct on spermine 
stimulation and indicate that there is one spermine binding site in NR2B-R. 
 
Determination of amino acid residues at the R domain of NR1A and NR2B which 
are involved in ifenprodil inhibition at -20mV 
        Ifenprodil is an atypical noncompetitive antagonist at the NR1/NR2B NMDA 
receptor. We previously found that mutations at NR1 (D130) influence ifenprodil 
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inhibition [64]. In this study we screen each mutation by measuring ifenprodil inhibiton 
at -20mV with 1 mM ifenprodil. If ifenprodil inhibition decreased³150% in the mutants 
compared with those of wild type NMDA receptor, it is judged that mutant amino acid 
residues are involved in ifenprodil inhibition, respectively. 
 
        Results on NR1A and NR2B mutants are shown in Fig. 15 and 17. Mutations 
at the amino acid residues from 100 to 134 of NR1A near NR1 (D130) have a strong 
effect on ifenprodil inhibition. It suggests that there is a ifenprodil binding sites in 
NR1A-R. Mutation from 100 to 114 amino acid residues of NR2B show a strong effct 
on ifenprodil inhibition and that indicate there is one ifenprodil binding site in NR2B-R. 
 
Molecular modeling of the NR1A-R and NR2B-R and docking of spermine and 
infenprodil 
 We built a 3D model of the R domain of NR1A and NR2B using the 
agonist-binding domain (ABD) of the metabotropic glutamate receptor mGluR1 as a 
template(PDB code 1EWK:A) [96]. Three dimensional structures of NR1A-R and 
NR2B-R were constructed by homology modeling with the Amber99 force field in 
MOE (version 2007.09, CCG Inc., Montreal, Canada). 3D model were generated using 
the alignment shown in Fig. 18. Because the sequence identity between NR1A or NR2B  
and mGlur1 ABD is very low (~18%), we base our alignment according to known 
(mGluR1 ABD) and predicted NR1A-R and NR2B-R secondary structure elements (Fig. 
18) . However , because the sequence of the NR1A-R and NR2B share such a low 
sequence with mGluR1 ABD, the orientations of residues side-chains are rather 
imprecise. Thorough functional validation of these model are therefore mandatory to 
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comfirm its biological relevance. 
Furthermore, the structure of the docking complex between NR1A-R and 
spermine, NR1A-R and ifenprodil, NR2B-R and spermine, and NR2B-R and ifenprodil 
were predicted with ASEDock of MOE. The resulting three-dimensional structure of 
each complex was displayed using MolFeat (Ver. 3.6, FiatLux, Tokyo, Japan). We 
found that there are two spermine binding sites in the 3D model of NR1A-R, one binds 
into the cleft of the 3D model of NR1A shown in Fig. 19 and the other binds on the 
surface. While there is only one ifenprodil binding site on the surface of 3D model of 
NR1A-R. These results indicate that there are two spermine binding sites and one 
ifenprodil biding site at NR1A-R, respectively. We also found that there is one 
sepermine binding site in the surface and one ifenprosil binding site in the cleft of the 
3D model of NR2B-R. This result incicates that there is one spermine and one 
ifenprodil binding site at NR2B-R, respectively.  
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Fig. 14  Effects of spermine at mutate NMDA receptors in NR1A.  
Effect of spermine (100 mM) were detemined in oocytes expressing NR1A/NR2B 
receptors with wild-type or mutant NR1A subunits, voltage-clamped at -20mV and 
activate by 10 mM glutamate and 10 mM glycine . Values are mean ±S.E.M. from 20 
oocytes for wild type and four oocytes for each mutant. Wild type are shown by red 
boxes. Mutations that reduced stimulation by ³20% compared with wild type are shown 
in yellow boxes. 
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Fig. 15  Effects of ifenprodil at mutate NMDA receptors in NR1A.      
Effect of ifenprodil (1 mM) were detemined in oocytes expressing NR1A/NR2B 
receptors with wild-type or mutant NR1A subunits, voltage-clamped at -20mV and 
activate by 10 mM glutamate and 10 mM glycine . Values are mean ±S.E.M. from 20 
oocytes for wild type and four oocytes for each mutant. Wild type is shown by red box. 
Mutations that reduced inhibition by ³150% compared with wild type are shown in 
yellow boxes. 
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Fig. 16  Effects of spermine at mutate NMDA receptors in NR2B.  
Effect of spermine (100 mM) were detemined in oocytes expressing NR1A/NR2B 
receptors with wild-type or mutant NR2B subunits, voltage-clamped at -20mV and 
activate by 10 mM glutamate and 10 mM glycine . Values are mean ±S.E.M. from 20 
oocytes for wild type and four oocytes for each mutant. Wild type are shown by red 
boxes. Mutations that reduced stimulation by ³20% compared with wild type are shown 
in yellow boxes. 
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Fig. 17  Effects of ifenprodil at mutate NMDA receptors in NR2B.    
Effect of ifenprodil (1 mM) were detemined in oocytes expressing NR1A/NR2B 
receptors with wild-type or mutant NR2B subunits, voltage-clamped at -20mV and 
activate by 10 mM glutamate and 10 mM glycine . Values are mean ±S.E.M. from 20 
oocytes for wild type and four oocytes for each mutant. Wild type is shown by red box. 
Mutation that reduced inhibition by ³150% compared with wild type are shown in 
yellow boxes. 
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Fig. 18 Multiple amino acid sequence alignment of NR1A-R and NR2B-R  with the 
agonist-binding domain of mGluR1.  
The indicated a-helix (red) and b-strands (blue) of mGluR1 are from the X-ray structure 
of the agonist-binding domain of mGluR1 (PDB: 1EWK: A). Secondary structure 
elements of NR1A-R and NR2B-R and the sequence alignment s were predicated using 
MOE.  
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Fig. 19 3D model of spermine and ifenprodil binding into the R-domain of NR-1A. 
The 3D model of NR1A-R shows a projected structure based on the known crystal 
structure of agonist-binding domain of mGluR1.  
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Fig. 20 3D model of spermine and ifenprodil binding into the R-domain of NR-2B. 
The 3D model of NR2B-R shows a projected structure based on the known crystal 
structure of agonist-binding domain of mGluR1.  
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Discussion 
       Several studies have reported the homology modeling of R domain of the 
NMDA receptors. [97, 98, 99] In more recent studies NR1A-R or NR2B 3D model was 
described with periplasmic binding proteins (LIVBP) and metabotropic glutamate 
receptors (mGluRs) as template. [97, 98, 99] Their studies on homology modeling show 
that ifenprodil binds into the cleft of the NR2B-R. We have used a similar approach to 
study the homology modeling of NR1A-R and NR2B-R, then spermine and ifenprodil 
were docked into the homology model. In our study we found that there are two 
spermine binding sites ( one is on surface and the other is into the cleft of NR1A-R 3D 
model) and one ifenprodil binding site at NR1A-R, but one spermine binding site on the 
surface and one ifenprodil biding site into the cleft of NR2B-R 3D model. It is reported 
that ifenprodil is a novel NMDA antagonist that selectively inhibits NR1/NR2 receptors 
containing the NR2B subunit and binding of ifenprodil into the cleft of NR2B-R 
controls the high-affinity ifenprodil inhibition. [98, 99] It suggest that binding into the 
cleft will get a more conformation change of the NMDA receptor than biding on surface. 
Therefore our results suggest that it is important for sepermine binding to NR1A-R 
because one spermine binding site is in the cleft. It also indicates that it is important for 
ifenprodil biding to NR2B-R.  
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